NEW YORK, June 15, 2007 /PRNewswire/ -- Telomerase Activation Sciences, Inc. (T.A. Sciences) recently announced the results of the Pivotal 2005 Anti-Aging Trial of TA-65, the first human trial ever to show demonstrated, measurable and positive anti-aging benefits from a Telomerase Activator. Statistically significant results were found in those taking TA-65 across several key conditions of aging:
-- Improvement in immune system function -- Improvement in vision -- Enhancement of male sexual function -- Improvement in the condition of the skin -- Increased level of energy and sense of overall well being
The Pivotal 2005 Anti-Aging Trial was a double blind, placebo-controlled, 24 week study conducted in the USA involving 36 male subjects aged 60-85.
The most compelling result of the Trial was the profound and positive impact of TA-65 on the immune system, which normally declines with age, leading to many negative conditions commonly associated with aging.
Noel Thomas Patton, Founder and Chairman of TA Sciences said: "Taken together, the results of the Pivotal 2005 Anti-Aging Trial of TA-65 provide the first proof ever recorded of the vast, powerful, and tangible benefits of a Telomerase Activator in human aging. This trial has been invaluable to our establishment of the "PATTON PROTOCOL."
Find Out More on July 7, 2007 On Saturday, July 7, 2007 at 6PM EST speakers include: -- Bill Andrews, Ph.D. Vice-President of research at Sierra Sciences Lab who, while Director of Molecular Biology at Geron Corporation was one of the principal discoverers of the telomerase genes. -- Jochen Kumm, Ph.D. Bio- Mathematics Director for the Stanford Genome Project. -- Physioage Medical Group Co-Founder Joseph Raffaele, M.D. -- TA Sciences founder Noel Patton.
The group will be disc